Cargando…
Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature
BACKGROUND: Renal toxicity has been reported with bisphosphonates such as pamidronate and zolidronate but not with ibandronate, in the treatment of breast cancer patients with bone metastasis. One of the patterns of bisphosphonate-induced nephrotoxicity is focal segmental glomerulosclerosis (FSGS) o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4510889/ https://www.ncbi.nlm.nih.gov/pubmed/26197890 http://dx.doi.org/10.1186/s12885-015-1536-y |
_version_ | 1782382257750671360 |
---|---|
author | Jia, Ning Cormack, Fionnuala C. Xie, Bin Shiue, Zita Najafian, Behzad Gralow, Julie R. |
author_facet | Jia, Ning Cormack, Fionnuala C. Xie, Bin Shiue, Zita Najafian, Behzad Gralow, Julie R. |
author_sort | Jia, Ning |
collection | PubMed |
description | BACKGROUND: Renal toxicity has been reported with bisphosphonates such as pamidronate and zolidronate but not with ibandronate, in the treatment of breast cancer patients with bone metastasis. One of the patterns of bisphosphonate-induced nephrotoxicity is focal segmental glomerulosclerosis (FSGS) or its morphological variant, collapsing focal segmental glomerulosclerosis (CFSGS). CASE PRESENTATION: We describe a breast cancer patient who developed heavy proteinuria (protein/creatinine ratio 9.1) and nephrotic syndrome following treatment with oral ibandronate for 29 months. CFSGS was proven by biopsy. There was no improvement 1 month after ibandronate was discontinued. Prednisone and tacrolimus were started and she experienced a decreased in proteinuria. CONCLUSION: In patient who develops ibandronate-associated CFSGS, proteinuria appears to be at least partially reversible with the treatment of prednisone and/or tacrolimus if the syndrome is recognized early and ibandronate is stopped. |
format | Online Article Text |
id | pubmed-4510889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45108892015-07-23 Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature Jia, Ning Cormack, Fionnuala C. Xie, Bin Shiue, Zita Najafian, Behzad Gralow, Julie R. BMC Cancer Case Report BACKGROUND: Renal toxicity has been reported with bisphosphonates such as pamidronate and zolidronate but not with ibandronate, in the treatment of breast cancer patients with bone metastasis. One of the patterns of bisphosphonate-induced nephrotoxicity is focal segmental glomerulosclerosis (FSGS) or its morphological variant, collapsing focal segmental glomerulosclerosis (CFSGS). CASE PRESENTATION: We describe a breast cancer patient who developed heavy proteinuria (protein/creatinine ratio 9.1) and nephrotic syndrome following treatment with oral ibandronate for 29 months. CFSGS was proven by biopsy. There was no improvement 1 month after ibandronate was discontinued. Prednisone and tacrolimus were started and she experienced a decreased in proteinuria. CONCLUSION: In patient who develops ibandronate-associated CFSGS, proteinuria appears to be at least partially reversible with the treatment of prednisone and/or tacrolimus if the syndrome is recognized early and ibandronate is stopped. BioMed Central 2015-07-22 /pmc/articles/PMC4510889/ /pubmed/26197890 http://dx.doi.org/10.1186/s12885-015-1536-y Text en © Jia et al. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Jia, Ning Cormack, Fionnuala C. Xie, Bin Shiue, Zita Najafian, Behzad Gralow, Julie R. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature |
title | Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature |
title_full | Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature |
title_fullStr | Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature |
title_full_unstemmed | Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature |
title_short | Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature |
title_sort | collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4510889/ https://www.ncbi.nlm.nih.gov/pubmed/26197890 http://dx.doi.org/10.1186/s12885-015-1536-y |
work_keys_str_mv | AT jianing collapsingfocalsegmentalglomerulosclerosisfollowinglongtermtreatmentwithoralibandronatecasereportandreviewofliterature AT cormackfionnualac collapsingfocalsegmentalglomerulosclerosisfollowinglongtermtreatmentwithoralibandronatecasereportandreviewofliterature AT xiebin collapsingfocalsegmentalglomerulosclerosisfollowinglongtermtreatmentwithoralibandronatecasereportandreviewofliterature AT shiuezita collapsingfocalsegmentalglomerulosclerosisfollowinglongtermtreatmentwithoralibandronatecasereportandreviewofliterature AT najafianbehzad collapsingfocalsegmentalglomerulosclerosisfollowinglongtermtreatmentwithoralibandronatecasereportandreviewofliterature AT gralowjulier collapsingfocalsegmentalglomerulosclerosisfollowinglongtermtreatmentwithoralibandronatecasereportandreviewofliterature |